Search

Abstract Quinoline‐based fibroblast activation protein (FAP) inhibitor (FAPI)‐based positron emission tomography (PET) imaging and radioligand therapy (RLT) are being investigated for use in a wide variety of diseases, and recent results have been promising. This review summarizes the current status of FAPI radiopharmaceuticals in PET imaging of malignant tumors and benign conditions and compares their diagnostic efficacy with 18F‐fluorodeoxyglucose. In addition, we summarize the previously published FAP‐targeted RLT data and discuss its current clinical use and future potential. Our qualitative summary can inform future research directions, medical guidelines, and optimal clinical decision‐making.

This paper investigates the compression detection problem using sub-Nyquist radars, which is well suited to the scenario of high bandwidths in real-time processing because it would significantly reduce the computational burden and save power consumption and computation time. A compressive generalized likelihood ratio test (GLRT) detector for sparse signals is proposed for sub-Nyquist radars without ever reconstructing the signal involved. The performance of the compressive GLRT detector is analyzed and the theoretical bounds are presented. The compressive GLRT detection performance of sub-Nyquist radars is also compared to the traditional GLRT detection performance of conventional radars, which employ traditional analog-to-digital conversion (ADC) at Nyquist sampling rates. Simulation results demonstrate that the former can perform almost as well as the latter with a very small fraction of the number of measurements required by traditional detection in relatively high signal-to-noise ratio (SNR) cases.